Flash | 10 Jun 2026 01:49:46 ET │ 10 pages CSL Ltd (CSL.AX) Sanofi's C1 inhibitor stopped for futility in refractory CIDP CITI'S TAKE We note that Sanofi (covered by Graham Parry) has today announced discontinuation of the phase III MOBILIZE trial for riliprubart monotherapy in refractory CIDP following interim futility analysis, and is evaluating whether to continue with other trials in the program. CIDP is the largest indication into which CSL sells Ig (c.22% of total Ig sales) and potential competitive t ...